Sonus and Abbott re-negotiate marketing deal
This article was originally published in Clinica
Executive Summary
Abbott is to cut back royalty payments to Sonus Pharmaceuticals for international sales of Sonus' second-generation ultrasound contrast imaging agent, EchoGen. The move is part of an amendment to the two companies' marketing and distribution agreement for the product, which is pending US approval.